Background
Methods
Subjects
Data collection and evaluation
Statistical analyses
Results
Patient characteristics
all patients (n = 24) | previous mepolizumab treatment (−) (n = 13) | previous mepolizumab treatment (+) (n = 11) | p value between two groups | |
---|---|---|---|---|
male, n (%) | 9 (38) | 4 (31) | 5 (45) | 0.68† |
age (years), mean (SD) (range) | 57.5 (13.4) (20–75) | 56.7 (15.8) (20–75) | 58.4 (10.6) (38–72) | 0.91‡ |
disease duration, (years), mean (SD) (range) | 21.3 (12.5) (4–54) | 21.2 (14.2) (4–54) | 21.5 (10.7) (8–36) | 0.68‡ |
body mass index (kg/m2), mean (SD) | 23.4 (4.8) | 24.6 (5.1) | 21.9 (4.1) | 0.19‡ |
smoking (never/former), n | 18 / 6 | 9 / 4 | 9 / 2 | 0.65† |
initial treatments use | ||||
—ICS/LABA, n (%) | 24 (100) | 13 (100) | 11 (100) | – |
—ICS dose (μg), mean (SD), budesonide equivalent | 1381 (448) | 1411 (518) | 1345 (370) | 0.66‡ |
—LAMA, n (%) | 14 (58) | 7 (54) | 7 (64) | 0.70† |
—LTRA, n (%) | 20 (83) | 11 (85) | 9 (82) | > 0.99† |
—xanthine derivative, n (%) | 17 (71) | 9 (69) | 8 (73) | > 0.99† |
—maintenance therapy of OCS, n (%) | 8 (33) | 6 (46) | 2 (18) | 0.21† |
—daily dose of OCSa (mg), mean (range) | 5.6 (1.0–15) | 6.1 (1.0–15) | 4.3 (2.5–6) | 0.74‡ |
comorbidities | ||||
—ECRS, n (%) | 20 (83) | 10 (77) | 10 (91) | 0.60† |
—EOM, n (%) | 11 (46) | 3 (23) | 8 (73) | 0.038† |
—AERD, n (%) | 7 (29) | 6 (46) | 1 (10) | 0.08† |
—EGPA, n (%) | 4 (17) | 1 (8) | 3 (27)b | 0.30† |
—atopic dermatitis, n (%) | 1 (4) | 1 (8) | 0 (0) | > 0.99† |
previous biologics | ||||
—omalizumab, n (%) / median (range) (month) | 5 (21) / 11 (3–88) | 1 (8) / 3 (3) | 4 (40) / 15.5 (4–88) | 0.14† / 0.16‡ |
—mepolizumab, n (%) / median (range) (month) | 11 (46) / 21 (5–35) | – | 11 (100) / 21 (5–35) | – |
—dupilumab, n (%) / median (range) (month) | 1 (4) / 6 (6) | 1 (8) / 6 (6) | – | – |
number of benralizumab injections, median (range) | 8 (2–11) | 8 (2–10) | 7 (4–11) | 0.98‡ |
observation period (months), median (range) | 11.5 (4–17) | 11 (4–16) | 14 (4–17) | 0.79‡ |
Clinical efficacy
all patients(n = 24) | previous mepolizumab treatment (−) (n = 13) | previous mepolizumab treatment (+) (n = 11) | P value between two groups at baseline | |||||||
---|---|---|---|---|---|---|---|---|---|---|
baseline | last follow up | P value | baseline | last follow up | P value | baseline | last follow up | P value | P value | |
peripheral blood eosinophil counts (/μl) | 292 (312) | 0 (0) | < 0.0001† | 458 (338) | 0 (0) | 0.0015† | 95 (88) | 0 (0) | 0.0033† | 0.0005† |
peripheral blood basophil counts (/μl) | 35 (27) | 7 (9) | < 0.0001† | 35 (26) | 6 (5) | 0.0015† | 35 (30) | 8 (13) | 0.0033† | 0.95 |
serum IgE (IU/ml) | 232(198) | 325 (674) | 0.70 | 263 (186) | 232 (225) | 0.48 | 196 (213) | 436 (980) | 0.88 | 0.27 |
FeNO (ppb) | 59 (39) | 67 (53) | 0.41 | 64 (43) | 71 (58) | 0.70 | 52 (32) | 61 (47) | 0.40 | 0.53 |
%FVC (%) | 94.9 (14.9) | 97.9 (14.3) | 0.11 | 96.1 (16.6) | 101.5 (14.2) | 0.028 | 93.4 (13.2) | 93.7 (13.9) | 0.76 | 0.52 |
%FEV1 (%) | 78.4 (21.9) | 81.9 (21.2) | 0.017 | 79.8 (26.2) | 84.6 (24.1) | 0.006 | 76.8 (16.6) | 78.8 (17.8) | 0.53 | 0.98 |
FEV1/FVC (%) | 67.2 (10.8) | 68.4 (12.3) | 0.29 | 67.1 (12.1) | 67.9 (12.5) | 0.35 | 67.2 (9.7) | 69.0 (12.7) | 0.53 | 0.75 |
FEV1 (ml) | 1978 (596) | 2057 (606) | 0.07 | 1936 (783) | 2053 (778) | 0.017 | 2026 (275) | 2061 (346) | 0.96 | 0.04 |
%PEF (%) | 83.9 (24.8) | 84.1 (24.4) | 0.72 | 86.6 (29.9) | 88.0 (27.5) | 0.70 | 80.6 (17.9) | 79.0 (19.8) | 0.22 | 0.88 |
ACT (pts) | 19.2 (4.8) | 20.3 (4.9) | 0.08 | 17.8 (5.9) | 20.2 (5.5) | 0.08 | 20.9 (1.8) | 20.3 (4.3) | 0.51 | 0.51 |
number of annual exacerbations | 2.8 (3.4) | 1.8 (3.2) | 0.28 | 3.6 (4.0) | 1.7 (3.5) | 0.10 | 1.8 (2.3) | 2.0 (2.8) | 0.67 | 0.31 |
prednisolone equivalent dose (mg/day) | 5.6 (4.2) | 3.3 (2.5) | 0.11 | 6.1 (4.7) | 3.0 (2.6) | 0.11 | 4.3 (2.5) | 4.3 (2.5) | – | 0.74 |
at baseline | GETE ≥ good (n = 14) | GETE ≤ moderate (n = 10) | p value | ΔFEV1 ≥ 200 ml (n = 8) | ΔFEV1 < 200 ml (n = 16) | p value |
---|---|---|---|---|---|---|
sex (M/F), n | 4 / 10 | 5 / 5 | 0.40 | 5 / 3 | 4 / 12 | 0.099 |
age (years) | 57.6 (12.1) | 57.2 (15.7) | 0.79 | 51.6 (15.8) | 60.4 (11.5) | 0.15 |
—MEPO (−) (n = 13) | 56.9 (12.6) (n = 8) | 56.4 (21.8) (n = 5) | 0.71 | 52.8 (19.4) (n = 5) | 59.1 (14.0) (n = 8) | 0.51 |
—MEPO (+) (n = 11) | 58.7 (12.6) (n = 6) | 58.0 (9.0) (n = 5) | 0.85 | 49.7 (10.2) (n = 3) | 61.6 (9.2) (n = 8) | 0.098 |
BMI (kg/m2) | 22.0 (4.2) | 25.3 (5.1) | 0.09 | 24.7 (5.5) | 22.7 (4.4) | 0.46 |
—MEPO (−) (n = 13) | 22.6 (5.0) (n = 8) | 27.7 (3.8) (n = 5) | 0.079 | 26.2 (5.0) (n = 5) | 23.5 (5.3) (n = 8) | 0.38 |
—MEPO (+) (n = 11) | 21.2 (2.9) (n = 6) | 22.8 (5.4) (n = 5) | 0.58 | 22.1 (6.3) (n = 3) | 21.8 (3.5) (n = 8) | 0.84 |
bEOS (/μl) | 306 (216) | 271 (426) | 0.20 | 407 (424) | 234 (234) | 0.27 |
—MEPO (−) (n = 13) | 437 (183) (n = 8) | 492 (531) (n = 5) | 0.66 | 565 (472) (n = 5) | 391 (236) (n = 8) | 0.66 |
—MEPO (+) (n = 11) | 132 (104) (n = 6) | 50 (35) (n = 5) | 0.20 | 143 (127) (n = 3) | 77 (71) (n = 8) | 0.31 |
bBASO (/μl) | 33 (29) | 38 (27) | 0.46 | 49 (40) | 28 (16) | 0.34 |
—MEPO (−) (n = 13) | 28 (18) (n = 9) | 46 (35) (n = 5) | 0.38 | 41 (37) (n = 5) | 31 (19) (n = 8) | 0.77 |
—MEPO (+) (n = 11) | 40 (40) (n = 6) | 29 (13) (n = 5) | 0.86 | 61 (51) (n = 3) | 26 (13) (n = 8) | 0.31 |
FeNO (ppb) | 70 (42) | 41 (26) | 0.08 | 70 (39) | 53 (38) | 0.26 |
—MEPO (−) (n = 13) | 74 (49) (n = 8) | 47 (30) (n = 5) | 0.27 | 66 (42) (n = 5) | 63 (48) (n = 8) | 0.71 |
—MEPO (+) (n = 10)a | 64 (33) (n = 6) | 33 (22) (n = 4)a | 0.11 | 75 (43) (n = 3) | 42 (23) (n = 7)a | 0.25 |
%FVC (%) | 99.1 (17.6) | 88.9 (7.2) | 0.04† | 83.8 (9.9) | 100.4 (14.0) | 0.005† |
—MEPO (−) (n = 13) | 101.0 (19.6) (n = 8) | 88.3 (5.9) (n = 5) | 0.04† | 84.6 (12.8) (n = 5) | 103.3 (15.1) (n = 8) | 0.04 |
—MEPO (+) (n = 11) | 96.7 (15.9) (n = 6) | 89.4 (9.0) (n = 5) | 0.47 | 82.3 (3.2) (n = 3) | 97.5 (13.1) (n = 8) | 0.07 |
%FEV1 (%) | 83.2 (22.8) | 71.7 (19.9) | 0.18 | 64.0 (12.9) | 85.6 (22.2) | 0.024† |
—MEPO (−) (n = 13) | 86.2 (20.6) (n = 8) | 69.5 (28.6) (n = 5) | 0.38 | 60.5 (14.3) (n = 5) | 91.8 (25.2) (n = 8) | 0.028† |
—MEPO (+) (n = 11) | 79.1 (13.1) (n = 6) | 74.0 (21.3) (n = 5) | 0.47 | 69.7 (9.5) (n = 3) | 79.4 (18.4) (n = 8) | 0.41 |
comorbidities | ||||||
—with AERD, n (%) | 2 (14) | 5 (50) | 0.085 | 3 (38) | 4 (25) | 0.65 |
—with ECRS, n (%) | 12 (86) | 8 (80) | > 0.99 | 7 (88) | 13 (81) | > 0.99 |
Analysis of clinical characteristics using multivariate logistic regression
GETE ≥ good (n = 14) | GETE ≤ moderate (n = 10) | odds ratio (95%CI) (univariate) | p value | odds ratio (95%CI) (multivariate) | p value | |
---|---|---|---|---|---|---|
sex (male), n (%) | 4 (29) | 5 (50) | 0.40 (0.07–2.2) | 0.29 | – | – |
age (≥ 65 year-old), n (%) | 5 (36) | 4 (40) | 0.83 (0.16–4.4) | 0.83 | – | – |
BMI (≥ 25) (kg/m2), n (%) | 3 (21) | 5 (50) | 0.27 (0.05–1.6) | 0.15 | 0.1 (0.004–2.8) | 0.18 |
bEOS (≥ 300) (/μl), n (%) | 7 (50) | 3 (30) | 2.3 (0.42–12.9) | 0.33 | 11.2 (0.57–219) | 0.11 |
bBASO (≥ 40) (/μl), n (%) | 4 (29) | 3 (30) | 0.93 (0.16–5.5) | 0.94 | – | – |
FeNO (≥ 50) (ppb), n (%) | 9 (64) | 3 (30) | 3.6 (0.62–21) | 0.15 | 3.7 (0.24–57) | 0.35 |
MEPO (+), n (%) | 6 (43) | 5 (50) | 0.75 (0.15–3.8) | 0.73 | – | – |
comorbidities | ||||||
—with AERD, n (%) | 2 (14) | 5 (50) | 0.17 (0.02–1.2) | 0.07 | 0.035 (0.002–0.72) | 0.03 |
—with ECRS, n (%) | 12 (86) | 8 (80) | 1.5 (0.17–13) | 0.71 | 0.51 (0.006–41) | 0.76 |